A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

[1]  K. Götze,et al.  Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia , 2007, Haematologica.

[2]  N. Chiorazzi.  Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. , 2007, Best practice & research. Clinical haematology.

[3]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[4]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[5]  J. Vose,et al.  Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[7]  M. Czuczman,et al.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Mayr,et al.  Current status of immunotherapy in B cell malignancies. , 2006, Current drug targets.

[9]  C. Peschel,et al.  Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab , 2006, British journal of haematology.

[10]  M. Konopleva,et al.  Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[11]  C. Peschel,et al.  Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells , 2006, Annals of Hematology.

[12]  E. Giné,et al.  How I treat refractory CLL. , 2006, Blood.

[13]  Stefano Volinia,et al.  Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. , 2006, Cancer research.

[14]  H. Prince,et al.  Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab * , 2006, British journal of haematology.

[15]  M. Hallek,et al.  Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Fonseca,et al.  Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Lane,et al.  The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.

[18]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[19]  C. Peschel,et al.  Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option , 2005, Leukemia & lymphoma.

[20]  H. Döhner,et al.  Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) , 2004, Leukemia.

[21]  C. Peschel,et al.  Expression of cyclin E in resting and activated B‐chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target , 2004, British journal of haematology.

[22]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[23]  V. Armstrong,et al.  Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. , 2002, Clinical chemistry.

[24]  F. Ajchenbaum‐Cymbalista,et al.  Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. , 1998, Blood.

[25]  John Calvin Reed.  Molecular biology of chronic lymphocytic leukemia. , 1998, Seminars in oncology.

[26]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[27]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[28]  P. Isaacson,et al.  Proliferation centres in B‐cell malignant lymphoma, lymphocytic (B‐CLL): an immunophenotypic study , 1994, Histopathology.

[29]  G. Capelli,et al.  Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B‐cell chronic lymphocytic leukemia , 2008, Cancer.

[30]  C. Dunn,et al.  Everolimus: a review of its use in renal and cardiac transplantation. , 2006, Drugs.

[31]  P. Circosta,et al.  Differential effects on CLL cell survival exerted by different microenvironmental elements. , 2005, Current topics in microbiology and immunology.

[32]  C. Peschel,et al.  Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. , 2003, Blood.